418. Primary resistance and RAMs to antiretroviral Etravirine (ETV) in HIV-1 patients from Santos, Brazil
Session: Poster Abstract Session: HIV - Antiretroviral Therapy
Friday, October 21, 2011
Room: Poster Hall B1
Background: ETV is a second generation NNRTI and shows no cross-resistance to other antiretrovirals in the same class of drugs. We decided to analyze the presence of primary resistance mutations to ETV in HIV positive individuals from Santos, São Paulo, Brazil.

Methods: 44 samples were evaluated. This study received institutional review board approval (043/2010). The viral nucleic acid was extracted using QIAamp blood and Viral Kit (Qiagen). PCR was carried out to amplify the RT region. The sequencing was performed using BigDye Terminator V3. Sequences were corrected and assembled with Sequencher Program (Gene Codes Corporation) and Bioedit (Carlsbad). Subtype was made using Stanford University website. 

Results: 86.4% of the samples were from the city of Santos, Praia Grande 6.8%, 4.5% and 2.3% from São Vicente and Guaruja. 50% of patients were men. The median of viral load was 4,4 copies/mL and the average CD4 was 302 mm3/mL. 45.5% of patients at the time of genotyping were being treated with of 2 NRTI + 2 PI and 27.3% were on 2 NRTI + 1 NNRTI. Two patients were not using medication. 68.3% of samples were subtype B, 29.3% of F/B and 2.4% of B/F. 24% of samples had K103N. In 13 sequences (31.7%) was found RAMs to the ETV, among them: 4.9% of V90I, 4.9% of A98G, 2.4% of L100I, 2.4% of K101E, 2.4% of K101H, 12.2% of V106I, 4.9% of Y181C and 9.8% of G190A. 3/44 samples was not possible to analyze the sequence.

Conclusion:Despite the high percentage of patients with mutation conferring resistance to other NNRTI only 4.4% had primary resistance mutation confer low susceptibility and 2.2% an intermediate response with use of ETV. We conclude that ETV may be used in the rescue treatment of patients with resistance to other NNRTI.


Subject Category: H. HIV/AIDS and other retroviruses

Eliane do Carmo Del-Duque1, Daniela Funayama1, Marcos Montani Caseiro2 and Shirley Vasconcelos Komninakis1, (1)Infectious Diseases Division / Federal University of Sao Paulo, Sao Paulo, Brazil, (2)Unilus - Fundacao Lusiadas de Santos, Sao Paulo, Brazil

Disclosures:

E. D. C. Del-Duque, None

D. Funayama, None

M. M. Caseiro, None

S. V. Komninakis, None

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.